The absence of an effective treatment against the coronavirus infection has led clinicians to redirect drugs that are known to be effective for other medical conditions to the treatment of COVID-19. Key among these repurposed therapeutic agents are the antimalarial drug chloroquine (CQ) and its analogue hydroxychloroquine (HCQ), which is used for the treatment of autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis.
Praised as a potential miracle cure, hundreds of trials got initiated across the globe for HCQ. Scientists started trying the drugs in low and high doses; alone or combined with other drugs in patients with mild or severe disease.
But this hope recently got struck by a big blow when a study came along claiming that these antimalarial drugs not only look ineffective but are downright deadly. This study, published on May 22 in the elite journal The Lancet, was conducted by three researchers- Dr Mandeep R Mehra from Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, US; Frank Ruschitzka from university Heart Center, University Hospital Zurich, Switzerland; and Dr Amit N Patel from Department of Biomedical Engineering, University of Utah, Salt Lake City, US.
They used hospital records procured by an American healthcare analytics company Surgisphere Corporation, established in 2008 by an Indian Sapan Desai, for their study. According to their findings, COVID-19 patients taking CQ or HCQ were associated with an increase in the risk of ventricular arrhythmias and a greater hazard for in-hospital death with COVID-19. The study concluded that these drug regimens should not be used outside of clinical trials and urgent confirmation from randomised clinical trials is needed.
この記事は Bio Spectrum の July 2020 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です ? サインイン
この記事は Bio Spectrum の July 2020 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です? サインイン
Early Diabetic Retinopathy Detection Remains a Challenge
The Vitreo Retinal Society of India (VRSI) and the Research Society for the Study of Diabetes in India (RSSDI) have formulated a first-of-its kind diabetic retinopathy (DR) screening guideline to help physicians and diabetologists in India educate their patients about DR.
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Qiagen launches QIAcuityDx digital PCR system for clinical testing in oncology
Qiagen N.V. has announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics.
Thermo Fisher introduces iCAP MX Series ICP-MS to simplify trace elemental analysis
Thermo Fisher Scientific Inc. has launched the Thermo Scientific iCAP MX Series ICP-MS to simplify trace element analysis with inductively coupled plasma mass spectrometry (ICP-MS).
Singleron, Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
IIT Madras identifies enhanced drug delivery method for eye treatments
Researchers at the Indian Institute of Technology Madras (IIT-M) have demonstrated how drugs injected in the human eye can be better delivered to the target region through ‘convection caused by mild laser heating’.
IIT Madras develops indigenous POCUS scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-Care-Ultrasound (POCUS) Scanner for sports injury diagnosis and management.
Practo strengthens Board with appointment of TVG Krishnamurthy and Dr Alexander Kuruvilla
Practo has appointed two new directors to its board: TVG Krishnamurthy and Dr Alexander Kuruvilla.
Dr R N Gupta steps in as National President of Indian Pharmaceutical Association
Dr R N Gupta has been elected as the National President of the Indian Pharmaceutical Association (IPA), the oldest and largest association of pharmaceutical professionals in the country, for the term 2024 - 2026 (October 1, 2024 - September 30, 2026).
QR678 brings medtech leader Sridhar Ranganathan to advisory board
QR678, a pioneering company dedicated to revolutionising hair and skin science through groundbreaking research and innovative solutions, has announced the appointment of Sridhar Ranganathan to its Board of Advisors.